Physician profile
David M Cola
NPI 1821023532
$853.32
in general payments reported to CMS, 2019-2025
14 companies · $15.83 in 2025
The $15.83 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $285 · 2021: $61.46 · 2022: $96.20 · 2023: $73.59 · 2024: $14.18 · 2025: $15.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $103.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $320.83 | 2019-2023 | |
| Abbvie INC. | $124.81 | 2019-2024 | Vraylar |
| Glaxosmithkline, LLC. | $76.11 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $59.42 | 2019-2022 | |
| Pfizer INC. | $49.25 | 2019-2021 | |
| Mylan Specialty L.P. | $39.18 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $34.43 | 2020 | |
| Vanda Pharmaceuticals INC. | $33.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.04 | 2023 | Stiolto Respimat |
| Lilly USA, LLC | $24.34 | 2019-2020 | |
| Allergan, INC. | $20.85 | 2020 | |
| Xeris Pharmaceuticals, INC. | $15.83 | 2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $12.62 | 2020 | |
| Amarin Pharma, INC. | $12.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.